Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
Patients enrolled in randomised clinical trials may not be representative of the real-world population of people with heart failure (HF). Older patients are frequently excluded and this limits the strength of evidence which supports the use of specific HF treatments in this patient group. Lack of ev...
Saved in:
Main Authors: | Davide Stolfo, Gianluigi Savarese |
---|---|
Format: | article |
Language: | EN |
Published: |
Radcliffe Medical Media
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/f4ce5f907c0d4c6c8732a6a7a88c5b12 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
by: Giuseppe MC Rosano, et al.
Published: (2019) -
The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
by: Osama A. Amin, et al.
Published: (2021) -
The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
by: Eliecer Coto, et al.
Published: (2021) -
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
by: Berkay Ekici, et al.
Published: (2021) -
Role of nutritional supplementation in heart failure with reduced ejection fraction
by: Yash Paul Sharma, et al.
Published: (2021)